BMRN stock sentiment todayBioMarin Pharmaceutical Inc.
Sentiment verdict
Gossip first, financials second — NEUTRAL at 70% confidence.
Last updated · cached analysis, refreshes periodically
BMRN
BioMarin Pharmaceutical Inc.BioMarin is undergoing a strategic pivot toward profitability and high-margin assets, but the slow launch of Roctavian remains a significant drag on sentiment.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for BMRN. Not financial advice.
Price · last 12 months
Gossip
The narrative is dominated by activist investor pressure from Elliott Investment Management, demanding cost-cutting and a refined portfolio strategy. While Voxzogo is a commercial success, the gene therapy Roctavian is widely viewed as a commercial disappointment, leading to rumors of a potential divestiture or scale-back.
- ·Activist investor involvement (Elliott)
- ·Voxzogo expansion in achondroplasia
- ·Skepticism over gene therapy commercialization
- ·Leadership transition and efficiency initiatives
Financial
BioMarin is transitioning from a high-spend biotech to a profitable specialty pharma entity. They boast a healthy cash position and increasing GAAP profitability, driven by the blockbuster trajectory of Voxzogo and steady enzyme replacement therapy revenues.
- ·Forward P/E approximately 18x-20x
- ·Double-digit revenue growth driven by Voxzogo
- ·Positive and growing free cash flow
- ·Robust balance sheet with over $1.5B in cash/investments
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·Insiders sold a net $1.2M on the open market in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Commercial failure of Roctavian to gain payer reimbursement
- ·Pipeline concentration risk in rare diseases
- ·Increasing competition in the achondroplasia market (e.g., BridgeBio)
- ·Execution risk during organizational restructuring
Peer temperature
How direct competitors stack up against BMRN right now.
- HOTBBIOBridgeBio Pharma
HOTTER — approaching potential launch of acoramidis and competing achondroplasia drug with higher near-term catalyst volatility.
See full analysis → - HOTSRPTSarepta Therapeutics
HOTTER — recently received expanded FDA label for Elevidys, offering superior growth velocity in the gene therapy space compared to Roctavian.
See full analysis → - NEUTRALVRTXVertex Pharmaceuticals
COLDER — while fundamentally superior, its massive market cap limits the 'takeover target' upside that BMRN possesses under activist pressure.
See full analysis →
- BMRN-2.5%
- BBIO+13.9%
- SRPT+2.2%
- VRTX+6.9%
Analyst price target
Consensus average of 24 analysts · median 88.00
Source: StockAnalysis.com · updated 2026-10-30
AI-generated analysis for informational purposes only. Not financial advice.